𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A long-term suppression by α-interferon of Philadelphia chromosome in children with chronic myelogenous leukemia

✍ Scribed by YOSHIHARU KIKAWA; YASUSHI FUJI; TOMOKO TAKANO; YOUSUKE SHIGEMATSU; MASAKATSU SUDO; MASANORI OKAMOTO; SHUKI MIZUTANI

Book ID
118711892
Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
387 KB
Volume
35
Category
Article
ISSN
1328-8067

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cutaneous sarcoidosis in a patient with
Cutaneous sarcoidosis in a patient with philadelphia-positive chronic myelogenous leukemia treated with interferon-α
✍ Yavorkovsky, Leonid L.; Carrum, George; Bruce, Suzanne; McCarthy, Philip L. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 17 KB 👁 3 views

A patient with Philadelphia-positive (Ph+) chronic myelogenous leukemia (CML) was diagnosed with cutaneous sarcoidosis after treatment with interferon-alpha (IFN-␣). Following IFN-␣ dose reduction, the skin lesions disappeared. Few cases of sarcoidosis associated with IFN treatment have been reporte

Intensive chemotherapy induction followe
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
✍ Hagop M. Kantarjian; Moshe Talpaz; Michael J. Keating; Elihu H. Estey; Susan O'b 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 585 KB

In a pilot study, 32 patients with Philadelphia chromosome-positive chronic myelogenous leukemia were treated with intensive chemotherapy induction followed by interferon-alpha (IFN-A) maintenance. Intensive chemotherapy consisted of three cycles of daunorubicin 120 mg/mz on day 1, cytarabine 80 mg/

Philadelphia chromosome-negative chronic
Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long term follow-up results
✍ Jorge E. Cortes; Moshe Talpaz; Miloslav Beran; Susan M. O'Brien; Mary B. Rios; S 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 594 KB

Background. Five to 10% of patients with chronic myelogenous leukemia (CML) do not have the Philadelphia chromosome (Ph), but one-third of them have rearrangements of the breakpoint cluster region (BCR-positive). Methods. The authors analyzed the characteristics, treatment response, and prognosis o